Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick N Harter

Showing results (41-50 of 205) with videos related to

Pageof 21
Sort By:
The Journal of Investigative Dermatology|October 6, 2016
High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV MelanomaBenjamin Weide, Tina Schäfer, Alexander Martens, et al.
Pathology, Research and Practice|December 1, 2019
High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastomaAnne K Braczynski, David Capper, David T W Jones, et al.
Histopathology|March 29, 2011
CD133 expression is associated with small round blue cell tumour morphology in human central nervous system neoplasmsJens Schittenhelm, Perikles Simon, Patrick N Harter, et al.
British Journal of Cancer|February 13, 2019
The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastomaMartha Foltyn, Anna-Luisa Luger, Nadja I Lorenz, et al.
Neoplasia (New York, N.Y.)|February 27, 2013
MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patientsKai Doberstein, Nico Steinmeyer, Ann-Kathrin Hartmetz, et al.
Neurosurgery|April 5, 2018
Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type GlioblastomasFlorian Gessler, Joshua D Bernstock, Anne Braczynski, et al.
Frontiers in Immunology|December 5, 2019
CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer ImmunotherapyMichael C Burger, Congcong Zhang, Patrick N Harter, et al.
Cerebellum (London, England)|March 22, 2022
The Acute Superficial Siderosis Syndrome - Clinical Entity, Imaging Findings, and HistopathologyLucie Friedauer, Christian Foerch, Joachim Steinbach, et al.
Biomedicines|January 8, 2025
Mossy Fiber Sprouting in Temporal Lobe Epilepsy: The Impact of Netrin-1, DCC, and Gene Expression ChangesMelis Onay, Patrick N Harter, Katherina Weber, et al.
Neurology|June 15, 2014
Sustained focal antitumor activity of bevacizumab in recurrent glioblastomaOliver Bähr, Patrick N Harter, Lutz M Weise, et al.
Pageof 21

Showing results (41-50 of 205) with videos related to

Sort By:
Pageof 21
The Journal of Investigative Dermatology|October 6, 2016
High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV MelanomaBenjamin Weide, Tina Schäfer, Alexander Martens, et al.
Pathology, Research and Practice|December 1, 2019
High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastomaAnne K Braczynski, David Capper, David T W Jones, et al.
Histopathology|March 29, 2011
CD133 expression is associated with small round blue cell tumour morphology in human central nervous system neoplasmsJens Schittenhelm, Perikles Simon, Patrick N Harter, et al.
British Journal of Cancer|February 13, 2019
The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastomaMartha Foltyn, Anna-Luisa Luger, Nadja I Lorenz, et al.
Neoplasia (New York, N.Y.)|February 27, 2013
MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patientsKai Doberstein, Nico Steinmeyer, Ann-Kathrin Hartmetz, et al.
Neurosurgery|April 5, 2018
Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type GlioblastomasFlorian Gessler, Joshua D Bernstock, Anne Braczynski, et al.
Frontiers in Immunology|December 5, 2019
CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer ImmunotherapyMichael C Burger, Congcong Zhang, Patrick N Harter, et al.
Cerebellum (London, England)|March 22, 2022
The Acute Superficial Siderosis Syndrome - Clinical Entity, Imaging Findings, and HistopathologyLucie Friedauer, Christian Foerch, Joachim Steinbach, et al.
Biomedicines|January 8, 2025
Mossy Fiber Sprouting in Temporal Lobe Epilepsy: The Impact of Netrin-1, DCC, and Gene Expression ChangesMelis Onay, Patrick N Harter, Katherina Weber, et al.
Neurology|June 15, 2014
Sustained focal antitumor activity of bevacizumab in recurrent glioblastomaOliver Bähr, Patrick N Harter, Lutz M Weise, et al.
Pageof 21